[HTML][HTML] Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
Y Beauverd, K Samii - International journal of hematology, 2014 - Springer
Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis with
demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly …
demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly …
[HTML][HTML] Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
Y Beauverd, K Samii - International Journal of Hematology, 2014 - ncbi.nlm.nih.gov
Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis with
demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly …
demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly …
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.
Y Beauverd, K Samii - International Journal of Hematology, 2014 - europepmc.org
Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis with
demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly …
demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly …
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
Y Beauverd, K Samii - International Journal of Hematology, 2014 - infona.pl
Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis with
demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly …
demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly …
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.
Y Beauverd, K Samii - International journal of hematology, 2014 - folia.unifr.ch
English Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis
with demonstrated efficacy for the alleviation of disease-related symptoms and …
with demonstrated efficacy for the alleviation of disease-related symptoms and …
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.
Y Beauverd, K Samii - International journal of hematology, 2014 - sonar.ch
English Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis
with demonstrated efficacy for the alleviation of disease-related symptoms and …
with demonstrated efficacy for the alleviation of disease-related symptoms and …
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
Y Beauverd, K Samii - International journal of hematology, 2014 - pubmed.ncbi.nlm.nih.gov
Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis with
demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly …
demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly …
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
Y Beauverd, K Samii - International Journal of Hematology, 2014 - search.proquest.com
Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelobrosis with
demonstrated efcacy for the alleviation of disease-related symptoms and splenomegaly …
demonstrated efcacy for the alleviation of disease-related symptoms and splenomegaly …
[引用][C] Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
Y BEAUVERD, K SAMII - International journal of hematology, 2014 - pascal-francis.inist.fr
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib
treatment discontinuation CNRS Inist Pascal-Francis CNRS Pascal and Francis …
treatment discontinuation CNRS Inist Pascal-Francis CNRS Pascal and Francis …